Upstate Medical University in Syracuse is one of 40 sites in the U.S. chosen to experiment a drug scientists say could potentially slow down dementia caused in Alzheimer’s patients.
The new drug is known as “troriluzole,” which early research has shown to normalize glutamate levels in the brain responsible for healthy intellectual function.
Experts suggest this process could slow down the progression of dementia, possibly even improving on the memory and thinking problems that get worse as the disease progresses.
As a result of its trial selection, Upstate’s now looking for patients with mild to moderate forms of Alzheimer’s Disease to participate in the experimental trial at no enrollment cost to them.
Here are the requirements for potential patients:
- 50 to 85-years-old
- On stable doses of donepezil (Aricept), or rivastigmine (Exelon) and galantamine (Razadyne) for at least three months or without memantine (Namenda)
- Not living in a nursing home
- Have a study partner who can attend visits and stay in regular contact;
- Must participate in the study for 48 weeks.
For more information about participating in the study, contact Colleen Dillenbeck at (315) 464-9014 or DillenCo@upstate.edu.